With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.17973-86-3,3,6-Dibromopyridazine,as a common compound, the synthetic route is as follows.
Step 1: 3,6-Dibromopyridazine (500 mg, 2.1 mmol), 4-(3-methoxy-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl)-l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazole (970 mg, 2.52 mmol), Pd(dppf)Ci2 (77 mg, 0.11 mmol), K2CO3 (870 mg, 6.3 mmol) were mixed in a Schlenk tube. The reaction was degassed with N2 for 15 min and dioxane (8 mL) and water (1 mL) were added and the reaction was heated to 90 C for 16 h. The reaction was cooled to room temperature, partitioned between EtOAc and water. The organic layers were dried over Na2S04, concentrated under vacuum, purified via column chromatography: eluting with gradient hexanes/EtOAc (0% to 40% EtOAc), column: silica 4 g, to provide 3-bromo-6-(2-methoxy-4-(l-(tetrahydro-2H-pyran- 2-yl)-lH-pyrazol-4-yl)phenyl)pyridazine (690 mg, 79%) as an off-white fluffy solid .
17973-86-3, As the paragraph descriping shows that 17973-86-3 is playing an increasingly important role.
Reference£º
Patent; PTC THERAPEUTICS, INC.; BABU, Suresh; BHATTACHARYYA, Anuradha; HWANG, Seongwoo; JANI, Minakshi; MOON, Young-choon; SYDORENKO, Nadiya; (214 pag.)WO2017/100726; (2017); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem